Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.


DURUSU TANRIÖVER M., Doganay H. L., AKOVA M., Guner H. R., Azap A., AKHAN S., ...Daha Fazla

Lancet (London, England), cilt.398, sa.10296, ss.213-222, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 398 Sayı: 10296
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/s0140-6736(21)01429-x
  • Dergi Adı: Lancet (London, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Psycinfo, Veterinary Science Database
  • Sayfa Sayıları: ss.213-222
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.